ULTRAGENYX PHARMACEUTICAL INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Pharmaceuticals

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $440,000.00 expenses · posted Apr 17, 2026

Lobbying activity 3

Health Issues

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Budget/Appropriations

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Medicare/Medicaid

Issues related to drug development, access and reimbursement for rare and ultra rare diseases.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.